Amylyx Pharmaceuticals Hires Stéphanie Hoffmann-Gendebien, MBA, as Head, General Manager EMEA
Amylyx Pharmaceuticals, Inc. today announced the appointment of Stéphanie Hoffmann-Gendebien, MBA, as Head, General Manager in Europe, the Middle East and Africa (EMEA). Ms. Hoffmann-Gendebien brings more than 20 years of leadership experience in the pharmaceutical and biotechnology industries with deep expertise in orphan drug development and commercialization. The first European entity of Amylyx, Amylyx Pharmaceuticals EMEA B.V., is incorporated in the Netherlands and is establishing a presence and team in Europe in order to be closer to the patient community, centers of excellence in medicine and regulatory authorities in regions for which Ms. Hoffmann-Gendebien will manage and oversee at Amylyx. Amylyx will establish its EMEA headquarters in the Zuidas district, Amsterdam, and plans a future expansion into the Middle East and Africa markets.
“At Amylyx, we are determined to help people living with ALS around the world. By expanding our organization in Europe, we can build deeper relationships with local ALS communities and understand their unique needs. With Stéphanie’s extensive global commercial and rare disease experience, and talent for developing long lasting partnerships with advocacy groups, researchers and clinicians, we are confident in her ability to lead Amylyx’ European organization,” said Margaret Olinger, Chief Commercial Officer at Amylyx. “Alongside an already impressive track record, we are certain with Stéphanie’s hands-on leadership style and can-do attitude, she will help us build an incredible team and significant presence across the continent. We’re truly honored to have her join the Amylyx team.”
In her career, Ms. Hoffmann-Gendebien has successfully led the launch of two orphan drugs in Europe and directed global market development, global patient advocacy, European market access and European launch planning for two additional orphan drugs. Most recently, Ms. Hoffmann-Gendebien served as managing director and founding partner of GH PARTNERS, a management consulting company providing consulting services for biotechnology companies involved in rare diseases and orphan drug development. GH PARTNERS provided guidance and consulting to companies related to market development, market access, patient advocacy, general management, orphan drug launch planning and commercialization.
“I was inspired by what I learned about the dedication and urgency with which the entire Amylyx team works to effectively advance AMX0035 through the clinical and commercial development process to help the global ALS community,” said Ms. Hoffmann-Gendebien. “Their willingness to listen and learn from advocacy groups to understand the unique needs of people with ALS is astonishing and makes me proud to join the company. Amylyx is at the forefront of advancing new treatments in neurodegenerative diseases and I am delighted to have the opportunity to develop this organization’s European presence and build out an agile team to serve this market.”
Prior to joining Amylyx, Ms. Hoffmann-Gendebien served as vice president, general manager, Europe, Middle East & Africa (EMEA) at Clementia Pharmaceuticals Inc. Prior to Clementia, she was the European director of strategic market development at Enobia Pharma (Alexion Pharmaceuticals, Inc.) and held roles of increasing responsibility in the therapeutics division Genzyme Europe BV (now Sanofi Genzyme). She serves on the board of directors at Secoya Technologies, a role she has held since April 2020, and volunteers with the European Organisation for Rare Diseases (EURORDIS), a non-governmental patient-driven alliance of rare disease patient organizations. Ms. Hoffmann-Gendebien received a bachelor’s degree in chemistry and an MBA from the Université catholique de Louvain in Louvain-la-Neuve, Belgium.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc. is a pharmaceutical company working on developing a novel therapeutic for Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases. For more information, visit www.amylyx.com and follow us on LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005775/en/
Contact information
Becky Gohsler
Finn Partners
(646) 307-6307
Becky.Gohsler@finnpartners.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EIG Acquires a 49.87% Stake in Transportadora de Gas del Perú (TgP)19.12.2025 19:42:00 EET | Press release
EIG, through its managed investment vehicles, acquired a 49.87% equity stake in Transportadora de Gas del Perú S.A. (“TgP”) from Canada Pension Plan Investment Board today. TgP operates Peru’s principal natural gas and natural gas liquids pipelines under a long-term concession, supplying approximately 40% of the country’s power generation. “We are delighted to complete this transaction and embark on the next chapter of our partnership with TgP,” said Matt Hartman, EIG’s Global Head of Infrastructure. “Our priority is to support TgP’s operational excellence and long-term stability, delivering value for customers and stakeholders throughout Peru.” About EIG EIG is a leading institutional investor in the global energy and infrastructure sectors with $24.3 billion assets under management as of September 30, 2025. EIG specializes in private investments in energy and energy-related infrastructure on a global basis. During its 43-year history, EIG has committed over $51.7 billion to the energ
CyberArk Named a Leader in IDC MarketScape: Worldwide Integrated Solutions for Identity Security 202519.12.2025 18:00:00 EET | Press release
CyberArk (NASDAQ: CYBR), the global leader in identity security, today announced that it has been recognized as a Leader in the IDC MarketScape: Worldwide Integrated Solutions for Identity Security 2025 Vendor Assessment. CyberArk extends dynamic privilege controls across all identity types with its unified platform, enabling organizations to improve efficiencies and streamline security operations. This IDC MarketScape report notes, “More change has occurred in the identity security marketplace in the past two years than in almost a decade. Vendors are entering a new phase defined by the emergence of intelligence technologies, none of which are specifically defined by any industry standards. Though different by design, the new adjacent IAM offerings are largely focused on improved vulnerability and threat management visibility and automated and predictive attack detection capabilities.” It also notes, “By addressing these evolving identity types within a unified framework, CyberArk enh
New York Liberty and Ant International’s Alipay+ Announce Multiyear Partnership Focused on Empowerment, Sustainability and Youth Development19.12.2025 15:30:00 EET | Press release
The New York Liberty and Ant International’s Alipay+, a leading cross-border fintech services platform based in Singapore, today announced a multiyear partnership, making Alipay+ an Official Sponsor and Innovation Partner for Sustainability of the New York Liberty. Through this partnership, Alipay+ and the Liberty will jointly support community programs designed to advance community empowerment, environmental sustainability and youth development across New York City. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219678825/en/ Peng Yang, CEO, Ant International and Clara Wu Tsai, Vice Chair, Brooklyn Sports and Entertainment; Governor, New York Liberty “Our partnership with Alipay+ goes beyond the game,” said Keia Clarke, Chief Executive Officer, New York Liberty. “Together, we are investing in the future of New York—its people, its environment, and its youth. Ant International’s commitment to community empowerment, sustai
Parse Biosciences and Codebreaker Labs Partner to Apply Whole Transcriptome Single Cell Profiling and Causal Genomics at Scale19.12.2025 15:00:00 EET | Press release
Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced a collaboration with Codebreaker Labs to develop and validate a breakthrough platform capable of testing thousands of genetic variants in parallel and measuring their effects at single cell resolution. By combining Codebreaker’s synthetic biology platform and variant engineering capabilities with the scale and accessibility of Parse’s Evercode™ technology, the collaboration aims to generate the causal data increasingly sought by AI developers, drug discovery teams, and clinical researchers. Today’s genomic studies rely heavily on observational data, or variants that appear in large populations. But rare and private variants, often only seen in one individual or family, are nearly impossible to study this way because too few carriers of the variant exist to draw statistically meaningful conclusions. As a result, even the most advanced models trained on observational datas
Cyviz Awarded Two Classified NATO Defense Contracts19.12.2025 09:00:00 EET | Press release
Norwegian technology and platform company Cyviz AS has been awarded two classified defense contracts by major European NATO-partner nations to deliver a fully mobile, containerised Command & Control (C2) capability, strengthening Europe’s operational readiness in high-threat and expeditionary environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218625485/en/ Image from a previous military exercise where Cyviz demonstrated a mobile command center solution. The contracts cover the design, integration, and delivery of secure, deployable operations centres engineered to NATO security standards, enabling military and security forces to establish full theatre-class command capability wherever operations require. Due to the sensitive nature of the missions, contract value and customer identities remain undisclosed. From Demonstrated Readiness to Operational Deployment The awards follow growing interest among European def
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom